GeneDx Holdings WGS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Business | ||||||
| GeneDx | $437.47M+33.4% | $423.09M+40.0% | $398.88M+50.5% | $360.81M+51.1% | $327.95M+52.4% | |
| Adjusted Gross Margin by Business | ||||||
| GeneDx | $311.15M+42.6% | $300.99M+53.6% | $282.89M+75.2% | $247.69M+81.4% | $218.27M+96.8% | |
| Adjusted cost of services by Business | ||||||
| GeneDx | $126.32M+15.2% | $122.1M+14.8% | $115.99M+11.9% | $113.11M+10.5% | $109.67M+5.2% | |
| Total Revenue by Product | ||||||
| Institutional customers | $68.29M+3.4% | $69.8M+7.2% | $68.19M+8.7% | $67.73M+10.9% | $66.05M+9.9% | |
| Patients with third-party insurance | $362.1M+39.8% | $345.24M+47.1% | $323.45M+63.2% | $287.97M+65.0% | $258.92M+69.2% | |
| Self-pay patients | $1.55M-16.1% | $1.36M-41.9% | $1.66M-23.5% | $1.5M-31.2% | $1.85M+2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does GeneDx Holdings break its business down?
- GeneDx Holdings (WGS) reports total revenue by business across 2 parts — GeneDx and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does GeneDx Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in GeneDx Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
